Ali Mortazavi, the long-serving chief executive of Silence Therapeutics PLC (LON:SLN), is stepping down from his role with immediate effect.
Mortazavi, who had been at the helm of the RNA therapeutics specialist for six years, will be replaced temporarily by the company’s chair, Annalisa Jenkins, until a permanent successor is found.
“On behalf of the board I would like to thank Ali for his achievements and commitment to Silence over the past six years,” said Jenkins.
“Under his leadership Silence has built an experienced international executive team with significant RNAi expertise that has established a strong IP and technology platform in GalNAC-based siRNA.”
Silence shares rose 6.7% to 144p in mid-morning trade.